Alps Group Inc Launches Pharmaco-Interaction (PCI) Unit via MyGenome, Debuting with CYP450 Drug Interaction Testing
原披露日期:;精度:秒。
来源:SEC(SEC EDGAR 6-K)。
查看原始披露 ↗原文限定:Certain statements in this press release may be considered to contain certain "forward-looking statements" within the meaning of "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "target," "believe," "expect," "will," "shall," "may," "anticipate," "estimate," "would," "positioned," "future," "forecast," "intend," "plan," "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on the Company's management's current beliefs, expectations, and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of our control. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements.
标题保留原文的计划、申请、条件、初步结果及否定状态,以原文为准。本站核验来源归属、证券身份及披露时间,不保证公司陈述或投资价值。
核验记录与处理时间
来源原始时间字段:2026-11-12T14:00:26.000Z;日期依据:SEC accepted filing time (Atom and index checked); calendar date is America/New_York; not an inferred press-release time。
采集层首次发现:2026-11-12T14:15:28.710Z;事件路径观察:2026-11-12T14:15:33.385Z。
处理开始:2026-11-12T21:00:49.477Z;处理完成:2026-11-12T21:00:52.293Z;首次资格通过:2026-11-12T21:00:52.293Z;首次公开:2026-11-12T21:00:52.293Z。
公开模式:natural_new;处理方式:automatic;规则版本:sec_company_events_v3_filed_release;自然时槽:2026-11-12T21:00:23.513Z。
保留原始披露及首次时间,重新展示不重写发布时间。
身份核验记录:2026-11-12T21:00:50.784Z;来源核验记录:2026-11-12T21:00:50.784Z。